about
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersThe feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulatiClass III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxelPaclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatmeCan biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.Metabolomics: available results, current research projects in breast cancer, and future applications.Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.Resistance to trastuzumab: a necessary evil or a temporary challenge?The European experience with docetaxel in the treatment of early-stage breast cancer.Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.Defining breast cancer intrinsic subtypes by quantitative receptor expression.Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-Chemotherapy for metastatic breast cancer.Controversies in the adjuvant treatment of breast cancer: the role of taxanes.Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancerCombination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical OncologyEndocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?Using specific cytotoxics with a targeted mind.New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer.Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerRecent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer.Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patientsMutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
P50
Q27853328-E374F727-CD28-4555-B8FA-E455A30F2294Q28081872-DA384D06-31C5-4CB2-AA23-59435135B4FCQ28216881-3458DF5F-2F14-43E0-978A-FDD6FDA1C120Q28287239-7B61494D-6157-498D-97D3-BE89BDFF5E6DQ30579243-948562F9-193D-4D88-938C-3A73F7513E29Q31050729-8366268C-8F38-4B1A-8123-86375598CD67Q33487862-158E6BE6-FE03-4FF3-8469-A7C8CC5B14EBQ33561588-64FB2E4A-EAC1-4041-883A-9D4ABA9CDAC9Q33820233-A861362A-1B34-4F6C-A782-DAA33023231CQ33900916-DFB02937-942B-40E8-A978-25956943999EQ33914753-DB8A5CF1-753A-4F2D-A0E1-CA1B14354140Q34019589-1B4AF797-D4B4-42D0-869F-12CFC6CCF682Q34023954-A59D88AD-4237-4A30-B0A0-E899377CE45AQ34417920-CC1212B1-07D0-41CC-B0B6-DE532E8960E1Q34628323-82194537-203C-48B7-B876-51392D309780Q34803601-216A9E2C-1293-4121-8D1C-40AF73AB3098Q34993786-4D70DD24-4848-4CB2-B4FD-77912B20A9AFQ34999345-175ABA5D-8B3B-47C3-978D-1676A2EAED79Q35019658-12F3A49F-6F1B-4B13-8543-E6FE317BCD85Q35586697-39A3908D-29F3-43E2-B087-D1D038A9D9D3Q35610564-ECFB5DA6-1A89-4D17-A664-6B930D7AF084Q35700216-8AEF82E8-318C-478A-9C5D-8F4A1EAAD28DQ35764917-52ED5508-0DEB-4EDD-98D5-39C6B6E40C11Q35914681-03F5B529-B038-4F41-BB0E-317FD10F925DQ36079441-001D3183-2068-4A01-B70A-8CEA1972CF83Q36080911-634000FE-0F90-4737-A0AC-7774A31E7959Q36081653-C19CE58F-D714-43A9-B351-5D79918841E2Q36245341-67F6EF70-FCE0-40B1-AB54-5F26623C9F8DQ36649978-9C2FB983-BC54-45B1-856B-EAC44282E0CFQ36743070-53C34D10-CABD-4125-8CE6-68FDBEEA8297Q36755089-C5A514C9-C6BF-450D-8E09-B81976326BCBQ36919536-9F2CBC3A-5BF9-41F5-860D-B26C09950CE6Q37033624-ADE3DC62-3D0D-42E4-AFB3-E3EE8A7340FBQ37117151-F7D531F7-4BFC-4BA0-ABD5-B9CB3E9F0404Q37208757-47D9695A-1F1B-4FFD-8389-584B9146D3AFQ37247163-745787EC-EFA3-4CF2-A7FA-82F277AF8C4BQ37321208-EEE08846-4948-4025-9493-A17EA860E5BEQ37328416-A4486141-A64A-40BF-8B1D-999A72C9FC95Q37394399-BAA45B34-D6D5-4DF2-9C29-7A04DD05A2A1Q37454306-499E87BE-F078-400E-A762-B7CC63AF1133
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Angelo Di Leo
@ast
Angelo Di Leo
@en
Angelo Di Leo
@es
Angelo Di Leo
@nl
Angelo Di Leo
@sl
type
label
Angelo Di Leo
@ast
Angelo Di Leo
@en
Angelo Di Leo
@es
Angelo Di Leo
@nl
Angelo Di Leo
@sl
prefLabel
Angelo Di Leo
@ast
Angelo Di Leo
@en
Angelo Di Leo
@es
Angelo Di Leo
@nl
Angelo Di Leo
@sl
P108
P106
P21
P214
767144928079054340225
P31
P496
0000-0002-3665-9056
P735
P7859
viaf-767144928079054340225